Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company agreed to be acquired by Roche at a price of $14.50 per share in cash at closing in September 2025, representing a premium of approximately 79% to 89bio's closing stock price on September 17, 2025.
Cyborg Score Rationale
Advanced clinical pipeline (Phase 3 trials) in high-value therapeutic areas (MASH, metabolic disease) with meaningful unmet medical needs. Acquisition by Roche at significant premium validates technology and market opportunity, though company is now transitioning from independent public entity.
Top Insights
Agreed to acquisition by global healthcare leader Roche in September 2025 at $14.50 per share, a 79% premium to pre-announcement closing price
Phase 3 trials for pegozafermin in MASH with advanced fibrosis and compensated cirrhosis, plus severe hypertriglyceridemia indication
Proprietary glycoPEGylated FGF21 analog technology designed to optimize biological activity and enable extended dosing intervals
Company completed IPO in November 2019 after founding in 2018
Named Competitors
FXF121 — FGF21 analog for metabolic disease
Semaglutide — GLP-1 analog for obesity and metabolic disease
Tirzepatide — GLP-1/GIP dual agonist for obesity and metabolic disease
Recent Developments
(September 2025) Merger agreement announced with Roche at $14.50 per share, 79% premium to pre-announcement stock price
(August 2025) Phase 3 ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis data expected in H1 2027 and 2028, respectively
Open the full interactive 89bio, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.